Picture: File Photo
Doha, Qatar: Hamad Medical Corporation's (HMC) Department of Laboratory Medicine and Pathology (DLMP) has successfully successfully achieved simultaneous reaccreditation of its laboratories by both the College of American Pathologists (CAP) and the Association for the Advancement of Blood and Biotherapies (AABB).
The formal CAP reaccreditation, awarded in March 2026, and AABB reaccreditation, granted in April 2026, followed intensive and coordinated inspections conducted in February, confirming full compliance with internationally recognized standards.
"This dual re-accreditation is a testament to the dedication, professionalism, and unwavering commitment of our DLMP teams across all divisions," said Dr. Einas Al Kuwari, Head of Laboratory Medicine and Pathology.
"Achieving simultaneous recognition from both CAP and AABB reflects our culture of continuous improvement and our enduring focus on patient safety, laboratory quality, and clinical excellence," she added.
The achievement reflects a high level of system-wide coordination, governance and institutional maturity, demonstrating DLMP's strong alignment and sustained commitment to laboratory quality, patient safety and clinical excellence.
The CAP lead inspector highlighted both the uniqueness and scale of the achievement, stating that HMC's quality management system was among the most extensive he had ever seen, while the AABB inspection team confirmed full compliance with international transfusion medicine and biotherapy standards.
Across the DLMP, accreditation readiness was demonstrated through compliance with 16,455 CAP standards and 479 AABB standards, supported by a comprehensive and integrated quality governance framework that includes 16 Ministry of Public Health (MOPH) indicators, 60 Quality and Patient Safety (QPS) indicators, 13 International Patient Safety Goals (IPSG) indicators, and 207 sectional indicators.
